Brainstorm Cell Therapeutics Inc.

Greetings, and welcome to the Brainstorm Cell Therapeutics Full Year 2021 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Good morning, and welcome.

Thank you for joining the call today with Brainstorm Cell Therapeutics. Before we begin the opening remarks, I'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the Neuron technology platform, clinical trials in Neuron and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control. including the risks and the certainties described from time to time in its SEC filings. The company's results may differ materially from those projected on today's call. The company undertakes no obligation to publicly update any forward-looking statements. Joining me on the call today will be President and CEO of Rainstorm, Chaim Leibowitz, Ala Patlis, Interim Chief Financial Officer. In addition, Dr. Stacey Lindberg, Executive VP and Chief Development Officer, Dr. Ralph Kern, President and Chief Medical Officer, And Dr. David Setburn, Executive VP and Chief Operating Officer, are also on the call and will be available to answer questions during the Q&A session. With that, I'd like to turn the call over to Mr. Leibowitz. Please go ahead.